Testicular cancer is by far the most common cancer among young men. Our work has identified an unusual ethnic inequality in testicular cancer, whereby Māori men suffer 80 per cent higher rates than European/Other men. This is in stark contrast to other international contexts, where it is the European/White population that suffer the highest rates of this disease. We are engaged in a programme of retrospective and prospective work that aims to explain this unusual disparity, with a view to both improving cancer outcomes for Māori and adding valuable new insights into the currently obscure causes of this cancer.
Ko te mate pukupuku i ngā raho te tino o ngā mate pukupuku ki waenga i ngā tama tāne. Kua tautohu mātau he tino rerekē te ōritenga kore mō te mate pukupuku i ngā raho ki waenga i ngā iwi, arā ka 80% te nui ake o te pānga o tēnei momo mate ki ngā tāne Māori i ngā tāne Pākehā me ētahi atu. He tino rerekē tēnei ki ētahi horopaki ki tāwāhi, arā ko te iwi Pākehā ka tino pāngia e tēnei mate. Kei te whakahaere mātau i tētahi hōtaka ki te titiro whakamuri, ki te titiro whakamua hoki ki te whakamārama i tēnei rerekētanga, me te whakaaro mā tēnei mahi e whakapiki ngā hua mate pukupuku mō Ngāi Māori, e whakaputa i te mātau hou ki ngā take o tēnei momo mate pukupuku e noho huna ana i tēnei wā.
Key publications
Jason Gurney, James Stanley, Katherine McGlynn, Lorenzo Richiardi, Caroline Shaw, Richard Edwards, Tony R Merriman, Bridget Robson, Jonathan Koea, Melissa McLeod, Martin Kennedy, Diana Sarfati (2018). The Testicular Cancer in New Zealand (TCNZ) study: Protocol for a national case-control study. BMJ Open, 8:e025212. doi:10.1136/bmjopen-2018-025212.
Jason K. Gurney, Andrea Ayers, Ariana Znaor, Jacques Ferlay, Mathieu Laversanne, Diana Sarfati, Freddie Bray, Katherine A. McGlynn. International trends in the incidence of testicular cancer: lessons from the last 35 years. European Urology, Accepted and In-Press. DOI: 10.1111/andr.12584
Signal V, Huang S, Sarfati D, Stanley J, McGlynn K, Gurney J. Diary and risk of testicular cancer: a systematic review. Nutrition and Cancer 2018; DOI: 10.1080/01635581.2018.1470655.
Huang S, Signal V, Sarfati D, Shaw C, Stanley J, McGlynn K, Gurney J. Physical activity and risk of testicular cancer: a systematic review. BMC Cancer 2018; 18:189: https://doi.org/10.1186/s12885-018-4093-3.
Gurney J, Stanley J, York S, Rosenbaum D, Sarfati D. Risk of lower limb amputation in a national prevalent cohort of patients with diabetes. Diabetologia 2018; 61: 626-35.
Gurney, J., Sarfati, D., Morreau, P., Stanley, J., Merriman, T., Signal, V., Shaw, C., Edwards, R., Richiardi, L., Hutson, J., McGlynn, K. (2017). Risk factors for congenital cryptorchidism. Nature Reviews Urology, doi:10.1038/nrurol.2017.90.
Gurney, J., Richiardi, L., McGlynn, K., Signal, V., Sarfati, D. (2016). Analgesia use during pregnancy and risk of cryptorchidism: a systematic review and meta-analysis. Human Reproduction, 32(5), p1118–1129.
Gurney, J., Stanley, J., Shaw, C., Sarfati, D. (2016). Ethnic patterns of hypospadias in New Zealand do not resemble those observed for cryptorchidism and testicular cancer: evidence of differential aetiology? Andrology, 4, p82-86.
Gurney, J., Shaw, C., Stanley, J., Signal, V., Sarfati, D. (2015). Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer, 15, p1-10.
Gurney, J., Sarfati, D., Stanley, J. (2015). Obscure etiology, unusual disparity: the epidemiology of testicular cancer in New Zealand. Cancer Causes and Control, 26, p. 561-569.
Gurney, J.K., Sarfati, D., Stanley, J., Studd, R. (2013) Do ethnic differences in cryptorchidism reflect those found in testicular cancer? The Journal of Urology, 190(5), p. 1852-1857.
Sarfati D, Shaw C, Blakely T, Atkinson J, Stanley J. Ethnic and Socioeconomic trends in testicular cancer incidence in New Zealand. International Journal of Cancer. 2011 128: 1683-91.
Presentations
Testicular cancer in New Zealand: A mystery to be solved:
Hear Dr Jason Gurney talking about the mysteries of testicular cancer aetiology, and the unique opportunity that we have in New Zealand to answer some fundamental questions about this disease.